Risk and prognostic factors for multidrug-resistant Acinetobacter baumannii complex bacteremia: A retrospective study in a tertiary hospital of West China

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Liu, Qianqian ^a   Li, Wenzhang ^b   Du, Xinmiao ^a   Li, Weijing ^a   Zhong, Taiqing ^a   Tang, Yin ^c   Feng, Yulin ^a   Tao, Chuanmin ^a   Xie, Yi ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

^c TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARBAPENEM; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; DRUG USE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; CROSS INFECTION; FEMALE; FOLLOW UP; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; SURVIVAL RATE;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHINA; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TERTIARY CARE CENTERS;

EID: 84939229059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130701     Document Type: Article

References (47)

1. Liu Q, Li W, Feng Y, Tao C. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis. PloS one. 2014; 9(6):e98091. doi: 10.1371/journal.pone.0098091 PMID: 24911658; PubMed Central PMCID: PMC4049575.
2. Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam medical journal. 2014; 50(2):37-44. doi: 10.4068/cmj.2014.50.2.37 PMID: 25229014; PubMed Central PMCID: PMC4161759.
3. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by gram-negative bacilli. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005; 41(6):848-54. doi: 10.1086/432803 PMID: 16107985.
4. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000; 31(3):690-7. doi: 10.1086/314040 PMID: 11017817.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2004; 39(3):309-17. doi: 10.1086/421946 PMID: 15306996.
6. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical care. 2006; 10(2):R48. doi: 10.1186/cc4869 PMID: 16563184; PubMed Central PMCID: PMC1550903.
7. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerging infectious diseases. 2007; 13(1):97-103. doi: 10.3201/eid1301.060716 PMID: 17370521; PubMed Central PMCID: PMC2725827.
8. Ho PL, Ho AY, Chow KH, Lai EL, Ching P, Seto WH. Epidemiology and clonality of multidrug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. The Journal of hospital infection. 2010; 74(4):358-64. doi: 10.1016/j.jhin.2009.10.015 PMID: 20153548.
9. Keen EF 3rd, Murray CK, Robinson BJ, Hospenthal DR, Co EM, Aldous WK. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2010; 31(7):728-32. doi: 10.1086/653617 PMID: 20500036.
10. Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Critical care medicine. 2014; 42(5):1081-8. doi: 10.1097/CCM.0000000000000125 PMID: 24394630.
11. Ng TM, Teng CB, Lye DC, Apisarnthanarak A. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2014; 35(1):49-55. doi: 10.1086/674387 PMID: 24334798.
12. Fukuta Y, Muder RR, Agha ME, Clarke LG, Wagener MM, Hensler AM, et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. American journal of infection control. 2013; 41(12):1249-52. doi: 10.1016/j.ajic.2013.04.003 PMID: 23870296.
13. Kim SB, Min YH, Cheong JW, Kim JS, Kim SJ, Ku NS, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scandinavian journal of infectious diseases. 2014; 46(2):81-8. doi: 10.3109/00365548.2013.857042 PMID: 24325335.
14. Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Research in microbiology. 2011; 162(4):393-404. doi: 10.1016/j.resmic.2011.02.006 PMID: 21320596.
15. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 52(3):352-60. doi: 10.1093/cid/ciq154 PMID: 21193494.
16. Clinical and Laboratory Standards Institute(CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014.
17. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012; 18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x PMID: 21793988.
18. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. International journal of antimicrobial agents. 1999; 11(1):7-12. PMID: 10075272.
19. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American journal of infection control. 2008; 36(5):309-32. doi: 10.1016/j.ajic.2008.03.002 PMID: 18538699.
20. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008; 46(8):1254-63. doi: 10.1086/529198 PMID: 18444865.
21. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. The Southeast Asian journal of tropical medicine and public health. 2011; 42(3):693-703. PMID: 21706949.
22. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. Journal of Korean medical science. 2012; 27(5):471-5. doi: 10.3346/jkms.2012.27.5.471 PMID: 22563209; PubMed Central PMCID: PMC3342535.
23. Luo L, Xie Y, He C, Qiao F, Zhuang H, Guo L, et al. Molecular epidemiological analysis of methicillin-resistant Staphylococcus aureus isolates from a medical intensive care unit: a comparison of nasal and clinical isolates. The American journal of the medical sciences. 2013; 345(5):361-5. doi: 10.1097/MAJ.0b013e31825b5443 PMID: 22868260.
24. Jacquier H, Le Monnier A, Carbonnelle E, Corvec S, Illiaquer M, Bille E, et al. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates. Microbial drug resistance. 2012; 18(4):396-401. doi: 10.1089/mdr.2011.0195 PMID: 22335615.
25. Lee JH, Choi CH, Kang HY, Lee JY, Kim J, Lee YC, et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. The Journal of antimicrobial chemotherapy. 2007; 59(4):633-9. doi: 10.1093/jac/dkm007 PMID: 17339277.
26. Chen IL, Lee CH, Su LH, Tang YF, Chang SJ, Liu JW. Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship. PloS one. 2013; 8(5):e65621. doi: 10.1371/journal.pone.0065621 PMID: 23738018; PubMed Central PMCID: PMC3667806.
27. Liu WL, Liang HW, Lee MF, Lin HL, Lin YH, Chen CC, et al. The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit. PloS one. 2014; 9(9):e107975. doi: 10.1371/journal.pone.0107975 PMID: 25255439; PubMed Central PMCID: PMC4177873.
28. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerging infectious diseases. 2008; 14(11):1722-30. doi: 10.3201/eid1411.070467 PMID: 18976555; PubMed Central PMCID: PMC2630720.
29. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(3):1152-6. PMID: 9927709; PubMed Central PMCID: PMC15366.
30. Steinke D, Davey P. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2001; 33 Suppl 3:S193-205. doi: 10.1086/321848 PMID: 11524719.
31. Gbaguidi-Haore H, Dumartin C, L'Heriteau F, Pefau M, Hocquet D, Rogues AM, et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. The Journal of antimicrobial chemotherapy. 2013; 68(2):461-70. doi: 10.1093/jac/dks406 PMID: 23075690.
32. Vernaz N, Huttner B, Muscionico D, Salomon JL, Bonnabry P, Lopez-Lozano JM, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. The Journal of antimicrobial chemotherapy. 2011; 66(4):928-35. doi: 10.1093/jac/dkq525 PMID: 21393172.
33. Opazo A, Sonnevend A, Lopes B, Hamouda A, Ghazawi A, Pal T, et al. Plasmid-encoded PER-7 beta-lactamase responsible for ceftazidime resistance in Acinetobacter baumannii isolated in the United Arab Emirates. The Journal of antimicrobial chemotherapy. 2012; 67(7):1619-22. doi: 10.1093/jac/dks087 PMID: 22419799.
34. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 2008; 21(3):538-82. doi: 10.1128/CMR.00058-07 PMID: 18625687; PubMed Central PMCID: PMC2493088.
35. Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. American journal of infection control. 2004; 32(6):342-4. doi: 10.1016/j.ajic.2004.02.008 PMID: 15454892.
36. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Critical care medicine. 2003; 31(4):1035-41. doi: 10.1097/01.CCM.0000060015.77443.31 PMID: 12682469.
37. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2002; 34(12):1600-6. doi: 10.1086/340616 PMID: 12032895.
38. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2007; 28(6):713-9. doi: 10.1086/517954 PMID: 17520546.
39. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. International journal of antimicrobial agents. 2010; 35(3):219-26. doi: 10.1016/j.ijantimicag.2009.10.024 PMID: 20047818.
40. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003; 9(5):412-8. PMID: 12848754.
41. Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. Journal of Korean medical science. 2011; 26(3):325-31. doi: 10.3346/jkms.2011.26.3.325 PMID: 21394298; PubMed Central PMCID: PMC3051077.
42. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrobial agents and chemotherapy. 2005; 49(2):760-6. doi: 10.1128/AAC.49.2.760-766-2005 PMID: 15673761; PubMed Central PMCID: PMC547233.
43. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of internal medicine. 1991; 115(8):585-90. PMID: 1892329.
44. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. The American journal of medicine. 1989; 87(5):540-6. PMID: 2816969.
45. Fleck A. Clinical and nutritional aspects of changes in acute-phase proteins during inflammation. The Proceedings of the Nutrition Society. 1989; 48(3):347-54. PMID: 2482490.
46. Anderson CF, Moxness K, Meister J, Burritt MF. The sensitivity and specificity of nutrition-related variables in relationship to the duration of hospital stay and the rate of complications. Mayo Clinic proceedings. 1984; 59(7):477-83. PMID: 6539842.
47. Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al. Polymicrobial bloodstream infection in neonates: microbiology, clinical characteristics, and risk factors. PloS one. 2014; 9(1):e83082. doi: 10.1371/journal.pone.0083082 PMID: 24454692; PubMed Central PMCID: PMC3891628.